Investor Relations



We are a leading science and technology company that delivers life-transforming medicines for serious diseases.

Founded by physician-scientists more than 30 years ago, our science-driven approach has resulted in eight FDA-approved medicines and numerous product candidates in a range of diseases, including cancer, asthma, pain and infectious diseases.

In addition to our medicines, our innovations include the VelociSuite® technologies, world-class manufacturing operations, one of the largest human sequencing efforts in the world and rapid response technologies being used for global good.




  • Feb 27

    Regeneron Announces Positive Phase 2 Data Evaluating Fel d 1 Antibody Cocktail in Cat-allergic Patients with Mild Asthma
  • Feb 26

    EMA Issues Advice on Regeneron's Antibody Cocktail (casirivimab with imdevimab) for Certain COVID-19 Patients


  • Oppenheimer 31st Annual Healthcare Conference
    Mar 16
    8:00 AM EDT
    Mar 16, 2021 | 8:00 AM EDT

  • Barclays Global Healthcare Conference
    Mar 10
    8:00 AM EST
    Mar 10, 2021 | 8:00 AM EST

  • Cowen 41st Annual Health Care Conference
    Mar 2
    9:10 AM EST
    Mar 2, 2021 | 9:10 AM EST